BDNF variability in opioid addicts and response to methadone treatment: Preliminary findings

Genes, Brain and Behavior

Volumn 7, Issue 5, 2008, Pages 515-522

  De Cid, R ^a   Fonseca, F ^b   Gratacos M ^a   Gutierrez, F ^c   Martin Santos R ^d   Estivill, X ^a,f,g   Torrens, M ^b,d,e,h  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b Drug Addiction Unit   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITAT POMPEU FABRA   (Spain)

^g Barcelona Biomedical Research Park   (Spain)

^h HOSPITAL DEL MAR   (Spain)

Author keywords

ASI; BDNF; Methadone; Opioid dependence; Pharmacogenetics; PRISM; Substance abuse; TCI

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GENOMIC DNA; METHADONE; OPIATE;

ADULT; AGED; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG USE; FEMALE; HAPLOTYPE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT ASSESSMENT; PERSONALITY; PRIORITY JOURNAL; PROTEIN VARIANT; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS;

ADULT; AGED; ANALGESICS, OPIOID; BRAIN-DERIVED NEUROTROPHIC FACTOR; COHORT STUDIES; COMORBIDITY; DRUG RESISTANCE; FEMALE; GENETIC VARIATION; HAPLOTYPES; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PERSONALITY; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 47249097896     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2007.00386.x     Document Type: Article

References (49)

1. Akbarian, S., Rios, M., Liu, R.J., Gold, S.J., Fong, H.F., Zeiler, S., Coppola, V., Tessarollo, L., Jones, K.R., Nestler, E.J., Aghajanian, G.K. Jaenisch, R 2002) Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. J Neurosci 22, 4153 4162.
2. Amato, L., Davoli, M., Perucci, C.A., Ferri, M., Faggiano, F. Mattick, R.P 2005) An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 28, 321 329.
3. Anderson, K.D., Alderson, R.F., Altar, C.A., DiStefano, P.S., Corcoran, T.L., Lindsay, R.M. Wiegand, S.J 1995) Differential distribution of exogenous BDNF, NGF, and NT-3 in the brain corresponds to the relative abundance and distribution of high-affinity and low-affinity neurotrophin receptors. J Comp Neurol 357, 296 317.
4. Barratt, D.T., Coller, J.K. Somogyi, A.A 2006) Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 141, 323 331.
5. Barrett, J.C., Fry, B., Maller, J. Daly, M.J 2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263 265.
6. Beuten, J., Ma, J.Z., Payne, T.J., Dupont, R.T., Quezada, P., Huang, W., Crews, K.M. Li, M.D 2005) Significant association of BDNF haplotypes in European-American male smokers but not in European-American female or African-American smokers. Am J Med Genet B Neuropsychiatr Genet 139, 73 80.
7. Brooner, R.K., King, V.L., Kidorf, M., Schmidt, C.W. Jr. Bigelow, G.E 1997) Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 54, 71 80.
8. Cacciola, J.S., Alterman, A.I., Rutherford, M.J., McKay, J.R. Mulvaney, F.D 2001) The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 61, 271 280.
9. Cloninger, C.R., Svrakic, D.M. Przybeck, T.R 1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50, 975 990.
10. Cloninger, C.R., Przybeck, T.R., Svrakic, D.M. Wetzel, R.D 1994) The Temperament and Character Inventory (TCI): a guide to its development and use. Center for Psychobiology of Personality, St Louis, MI.
11. Crettol, S., Deglon, J.J., Besson, J., Croquette-Krokar, M., Hammig, R., Gothuey, I., Monnat, M. Eap, C.B 2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80, 668 681.
12. Chao, M.V 2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4, 299 309.
13. Cheng, C.Y., Hong, C.J., Yu, Y.W., Chen, T.J., Wu, H.C. Tsai, S.J 2005) Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res 140, 86 90.
14. Dennis, K.E. Levitt, P 2005) Regional expression of brain derived neurotrophic factor (BDNF) is correlated with dynamic patterns of promoter methylation in the developing mouse forebrain. Brain Res Mol Brain Res 140, 1 9.
15. Ebstein, R.P 2006) The molecular genetic architecture of human personality: beyond self-report questionnaires. Mol Psychiatry 11, 427 445.
16. Egan, M.F., Kojima, M., Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., Lu, B. Weinberger, D.R 2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, 257 269.
17. Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S.N., Rotimi, C., Adeyemo, A., Cooper, R., Ward, R., Lander, E.S., Daly, M.J. Altshuler, D 2002) The structure of haplotype blocks in the human genome. Science 296, 2225 2229.
18. GAO 1990) Methadone maintenance: some treatment programs are not effective; greater Federal oversights needed. United States General Accounting Office, Washington, DC (GAO/HRD-90-104).
19. Gerra, G., Garofano, L., Castaldini, L., Rovetto, F., Zaimovic, A., Moi, G., Bussandri, M., Branchi, B., Brambilla, F., Friso, G. Donnini, C 2005) Serotonin transporter promoter polymorphism genotype is associated with temperament, personality traits and illegal drugs use among adolescents. J Neural Transm 112, 1397 1410.
20. Gonzalez, F., Salvador, L., Martinez, J.M., Lopez, A., Ruz, I. Guerra, D 2002) Estudio de fiabilidad y validez de la versión española de la entrevista clínica Addiction Severity Index (ASI). In Iraurgi, I., Gonzalez, F. (eds Instrumentos de evaluación en drogodependencias. Aula Medica Ediciones, Madrid, pp. 271 308.
21. Graham, D.L., Edwards, S., Bachtell, R.K., DiLeone, R.J., Rios, M. Self, D.W 2007) Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 10, 1029 1037.
22. Gratacos, M., Gonzalez, J.R., Mercader, J.M., de Cid, R., Urretavizcaya, M. Estivill, X 2007a) Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 61, 911 922.
23. Gratacos, M., Soria, V., Urretavizcaya, M., Gonzalez, J.R., Crespo, J.M., Bayes, M., de Cid, R., Menchon, J.M., Vallejo, J. Estivill, X 2007b) A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J Epub ahead of print Salamero, M 2001) Psychometric properties of the Temperament and Character Inventory (TCI) questionnaire in a Spanish psychiatric population. Acta Psychiatr Scand 103, 143 147.
24. Hasin, D., Samet, S., Nunes, E., Meydan, J., Matseoane, K. Waxman, R 2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163, 689 696.
25. Hirano, S., Sato, T., Narita, T., Kusunoki, K., Ozaki, N., Kimura, S., Takahashi, T., Sakado, K. Uehara, T 2002) Evaluating the state dependency of the Temperament and Character Inventory dimensions in patients with major depression: a methodological contribution. J Affect Disord 69, 31 38.
26. Itoh, K., Hashimoto, K., Shimizu, E., Sekine, Y., Ozaki, N., Inada, T., Harano, M., Iwata, N., Komiyama, T., Yamada, M., Sora, I., Nakata, K., Ujike, H. Iyo, M 2005) Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am J Med Genet B Neuropsychiatr Genet 132, 70 73.
27. Jiang, X., Xu, K., Hoberman, J., Tian, F., Marko, A.J., Waheed, J.F., Harris, C.R., Marini, A.M., Enoch, M.A. Lipsky, R.H 2005) BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30, 1353 1361.
28. Kellogg, S., Melia, D., Khuri, E., Lin, A., Ho, A. Kreek, M.J 2006) Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. J Addict Dis 25, 15 25.
29. Klump, K.L., Strober, M., Bulik, C.M., Thornton, L., Johnson, C., Devlin, B., Fichter, M.M., Halmi, K.A., Kaplan, A.S., Woodside, D.B., Crow, S., Mitchell, J., Rotondo, A., Keel, P.K., Berrettini, W.H., Plotnicov, K., Pollice, C., Lilenfeld, L.R. Kaye, W.H 2004) Personality characteristics of women before and after recovery from an eating disorder. Psychol Med 34, 1407 1418.
30. Kreek, M.J., Nielsen, D.A., Butelman, E.R. LaForge, K.S 2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8, 1450 1457.
31. Lake, S.L., Lyon, H., Tantisira, K., Silverman, E.K., Weiss, S.T., Laird, N.M. Schaid, D.J 2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55, 56 65.
32. Lang, U.E., Hellweg, R. Gallinat, J 2004) BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 29, 795 798.
33. Lang, U.E., Hellweg, R., Kalus, P., Bajbouj, M., Lenzen, K.P., Sander, T., Kunz, D. Gallinat, J 2005) Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 180, 95 99.
34. Lawford, B.R., Young, R.M., Noble, E.P., Sargent, J., Rowell, J., Shadforth, S., Zhang, X. Ritchie, T 2000) The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 96, 592 598.
35. Li, J. Ji, L 2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95, 221 227.
36. Liu, Q.R., Walther, D., Drgon, T., Polesskaya, O., Lesnick, T.G., Strain, K.J., de Andrade, M., Bower, J.H., Maraganore, D.M. Uhl, G.R 2005) Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 134, 93 103.
37. Liu, Q.R., Lu, L., Zhu, X.G., Gong, J.P., Shaham, Y. Uhl, G.R 2006) Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res 1067, 1 12.
38. Maisonpierre, P.C., Le Beau, M.M., Espinosa, R. III., Ip, N.Y., Belluscio, L., de la Monte, S.M., Squinto, S., Furth, M.E. Yancopoulos, G.D 1991) Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10, 558 568.
39. Marchesi, C., Cantoni, A., Fonto, S., Giannelli, M.R. Maggini, C 2006) The effect of temperament and character on response to selective serotonin reuptake inhibitors in panic disorder. Acta Psychiatr Scand 114, 203 210.
40. Matsushita, S., Kimura, M., Miyakawa, T., Yoshino, A., Murayama, M., Masaki, T. Higuchi, S 2004) Association study of brain-derived neurotrophic factor gene polymorphism and alcoholism. Alcohol Clin Exp Res 28, 1609 1612.
41. McLellan, A.T., Luborsky, L., Woody, G.E. O'Brien, C.P 1980) An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 168, 26 33.
42. Pattabiraman, P.P., Tropea, D., Chiaruttini, C., Tongiorgi, E., Cattaneo, A. Domenici, L 2005) Neuronal activity regulates the developmental expression and subcellular localization of cortical BDNF mRNA isoforms in vivo. Mol Cell Neurosci 28, 556 570.
43. Pruunsild, P., Kazantseva, A., Aid, T., Palm, K. Timmusk, T 2007) Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90, 397 406.
44. Rybakowski, J.K., Suwalska, A., Skibinska, M., Szczepankiewicz, A., Leszczynska-Rodziewicz, A., Permoda, A., Czerski, P.M. Hauser, J 2005) Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 38, 166 170.
45. Seroogy, K.B., Lundgren, K.H., Tran, T.M., Guthrie, K.M., Isackson, P.J. Gall, C.M 1994) Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 342, 321 334.
46. Thoenen, H 1995) Neurotrophins and neuronal plasticity. Science 270, 593 598.
47. Torrens, M., Serrano, D., Astals, M., Perez-Dominguez, G. Martin-Santos, R 2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161, 1231 1237.
48. Ward, J., Hall, W. Mattick, R.P 1999) Role of maintenance treatment in opioid dependence. Lancet 353, 221 226.
49. Williamson, A., Darke, S., Ross, J. Teesson, M 2007) The effect of baseline cocaine use on treatment outcomes for heroin dependence over 24 months: findings from the Australian Treatment Outcome Study. J Subst Abuse Treat 33, 287 293.